R&D Antibodies is managed by a team of very experienced and highly successful professionals with over 60 years of combined scientific project, clinical research, and company management experience.

R&D Antibodies has also assembled some of the top academic scientists in the bio-medical field to advise us on topics important to achieving our goals successfully. These preeminent scientist provide us with a broad spectrum of ideas and concepts important to advancing our research and development efforts.

Dr. Robert Webber trained at the UCLA School of Medicine in the Department of Biological Chemistry. His professional experience as founder, CEO and Chief Scientific Officer since 1984 of Research & Diagnostic Antibodies®, the parent company of R&D Antibodies, assures that he is capable of managing this enterprise and directing both the basic research and the clinical research efforts. He is a pioneer in producing monoclonal antibodies, their use as research tools, and their use in diagnostic tests. While he and his team of scientists were successfully conducting clinical trials for a new sepsis in vitro diagnostic (IVD) test, they convincingly proved plasma iNOS is an early biomarker for the onset of sepsis and can be used to monitor the course of the pathology. These research efforts culminated in the filing of patent applications to protect the clinical IVD tests that are emerging from their breakthrough discoveries. In 2003, Dr. Webber and his associates founded R&D Antibodies to commercialize the new clinical IVD test products that are based on these novel discoveries and new intellectual property.

Dr. Robert Webber is the inventor or co-inventor of multiple issued patents and pending USA and foreign patent applications that protect monoclonal antibodies specific for iNOS, immunoassays specific for iNOS, and methods and apparatuses for the detection iNOS in plasma as a clinical IVD test for sepsis and severe sepsis. The novel clinical products that are emerging from Dr. Webber’s pioneering work in this field should capture a significant portion of a greater than $850 million per year market for clinical IVD tests for sepsis and severe sepsis and should save tens-of-thousands, possibly hundreds-of-thousands, of lives per year worldwide.

In May 2010 Dr. Webber was awared a $2.6M NIH grant after thorough peer review of his grant application. This ongoing award is to collect the data needed to obtain FDA marketing clearance for the first accurate and reliable IVD test for the onset of the sepsis pathology.

In September 2012 Dr. Webber was awarded the 2012 "Researcher of the Year" award by the Nevada Biotechnology and Science Consortium (NevBio.org).

Dr. Richard Sweet received his M.D. at the University of Minnesota. He then completed his Internship, a three year Residency in Internal Medicine, and a two year Fellowship in Nephrology. Dr. Sweet became Board Certified in Internal Medicine, Nephrology, and Critical Care Medicine. He was the founder of the largest nephrology practice in Minnesota, the Kidney Specialists of Minnesota, and while there he was instrumental in developing a drug study program, Twin Cities Clinical Research. During this time Dr. Sweet participated in over 12 clinical trials including the use of therapeuitic monoclonal antibodies to treat sepsis and a trial natriuretic peptide in acute renal failure.

Dr. Sweet was Co-Director of Renal Transplantation at Abbott Northwestern Hospital in Minneapolis, and he helped found the Renal Transplant Program at the hospital. Dr. Sweet also founded one of the largest apheresis programs in the United States, and has given a number of presentations in extracorporeal filtration and immunoaffinity absorption.

Dr. Sweet is currently an Associate Clincal Professor of Medicine at the University of California, San Fransisco, Chief Medical Officer of Hemotherapeutics, Los Angeles, CA, and Chief Medical Officer at R&D Antibodies LLC, Las Vegas, NV. Dr. Sweet also serves on the Board of Directors at R4Vascular, Minneapolis, MN.

While serving as CMO at R&D Antibodies, Dr. Sweet has actively participated in writing and editing NIH grant applications and has interacted with the US FDA on the ongoing $2.6M NIH funded project to obtain marketing clearance for the first reliable and accurate IVD test for sepsis. Dr. Sweet is serving as site PI at UC San Fransisco School of Medicine and San Fransisco General Hospital for the clinical study.

Dr. Thelma H. Dunnebacke studied the development of the nervous system in chick embryos under the direction of Drs. Viktor Hamburger and Rita Levi-Montalcini at Washington University in St. Louis, Missouri from which she received her Ph.D. Dr. Dunnebacke has been associated with Research & Diagnostic Antibodies, the parent company of R&D Antibodies, since 1994 following the invitation to join the staff as a cell biologist and to participate in the preparation and use of cultured cells for the development of monoclonal antibodies. She was a leader of the original research team that recognized the presence of iNOS in the plasma of septic patients and showed it was an early signal for the onset of sepsis. She is a co-inventor of the plasma IVD test for iNOS and has led three different clinical studies that demonstrated the value of this IVD test as a very early diagnostic test for the onset of sepsis.

Her earlier research career has included studies at the Virus Laboratory at the University of California, Berkeley in association with Dr. Wendell Stanley and as an associate in the laboratory of Dr. Robley Williams. During her tenure at Research & Diagnostic Antibodies, Dr. Dunnebacke has also maintained her own research program at the Viral and Rickettsial Disease Laboratory at the State of California Department of Health Services. Currently, her work there is based on the study of free-living amebas that are opportunistic pathogens in humans and other animals and are the causative agent for amebic encephalitis, a devastating and usually fatal disease.

Dr. Dunnebacke is co-inventor on the issued patents and pending patent applications that have been filed to protect the intellectual property and clinical in vitro diagnostic (IVD) products developed to diagnose and monitor episodes of sepsis. She is also one of the founding partners of R&D Antibodies LLC.

Dr. Douglas Webber received his training at Tulane University School of Medicine and graduated with a Ph.D. While at Tulane, he studied the involvement of the Nitric Oxide and cGMP signing pathway (nNOS, soluble Guanylyl Cyclase, Protein kinase depended cGMP 1α, and Protein kinase depended cGMP 1β), and the location of these proteins in the central auditory system. As a Post-Doctorial Fellow in the David Geffen School of Medicine at UCLA, he investigated how auditory deficits occur with exposure to carbon monoxide during development.

Dr. Douglas Webber is co-PI on the ongoing $2.6M NIH grant and was instrumental in writing the grant application and obtaining FDA buy-in to the pivotal clinical study to obtain marketing clearance for the EIA test for plasma iNOS as a very early and accurate biomarker for the onset of sepsis. Dr. Douglas Webber is also one of the founding partners of R&D Antibodies LLC and is co-inventor on many of the issued patents and pending patent applications.

Home | News | R&D Vision | President's Message | Achievements | Leadership Team | Technology | Contact